In clinical practice, the most frequent question will be to determine which drug to add to the incretin that a patient with MASH is already receiving
Lancet 382 (9893), 720731 (2013)
Compared with the structure of human GLP-1(7-37), the amino acid sequence of dulaglutide contains glycine at position 8, glutamic acid at position 22, and glycine at position 36.113 It was then fused to the constant region (Fc) of modified human immunoglobulin G4 (IgG4) via a -(Gly-Gly-Gly-Gly-Ser) 3-Ala- bridge and exhibits an average biological half-life of 90 h.105 Dulaglutide is the first large-molecule GLP-1RA, and the weekly dosing frequency of dulaglutide can greatly improve patient compliance.33,78,104,114 Semaglutide Semaglutide is a long-acting GLP-1RA agent used once weekly to improve glycemic control in patients with T2DM.115 Compared with the structure of human GLP-1(7-37), the amino acid sequence of semaglutide contains diaminoisobutyric acid at position 8, arginine at position 34, and acylated lysine at position 26.31 Semaglutide has a longer aliphatic chain and increased hydrophobicity, but its hydrophilicity is greatly enhanced by PEG modification of the short chain
The label highlights 10 grams of protein, but a closer look shows about 30 grams of added sugar in the same serving, a reminder that "high protein" does not always mean healthy
Each pathway comes with its own implications for impurities, quality, potency, and scalability, making the choice an important strategic decision in drug development
In numerous personal injury practice areas, we have pioneered case theories and courtroom techniques that other law firms have used after observing our successes
